Commercial newswire·US·
Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Brooklyn's Go-To Public Adjuster, Republic Claims Associates, Expands Its National Reach
- AMY GREEN AND THE GREEN VISION FOUNDATION HOSTED THE FOOTPRINT OF LIFE DURING CLIMATE WEEK NYC
- PENTAIR CLASS ACTION DEADLINE FRIDAY: Bragar Eagel & Squire, P.C. Encourages Pentair plc Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 2nd
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →Shared via PPN World — real-time press release intelligence.